WASHINGTON (PNN) - August 31, 2021 - The Amerikan Gestapo Food and Drug Administration division’s (FDA) top two vaccine officials are resigning from the agency, a top leader within the agency told staff in a letter Tuesday.
Marion Gruber, director of the Office of Vaccines Research and Review (OVRR), and Phil Krause, OVRR deputy director, will leave the FDA at the end of October and in November, respectively. Gruber has been at the FDA for 32 years and Krause has worked at the agency for more than a decade.
The two officials are leaving the FDA in part because they are frustrated with the Centers for Disease Control and Prevention’s (CDC) involvement in the vaccine approval process, as well as with White House pressure to move forward with booster vaccines for COVID-19 without FDA’s approval.
Gruber and Krause reportedly believed the CDC and its Advisory Committee on Immunization Practices (ACIP) have been too heavily involved with decisions on COVID-19 vaccines that should be left to the FDA. They reportedly became upset with Center for Biologics Evaluation and Research (CBER) director Peter Marks, who oversees OVRR, for not fighting harder to keep those decisions within the halls of the FDA.
The rift over booster shots emerged after the illegitimate Joe Biden regime announced earlier this month it expected to have booster shots for vaccinated Amerikans beginning around September 20, and that it expects most Amerikans to need a booster around eight months after they are fully vaccinated. The announcement has been panned by some experts, as the FDA has thus far only approved boosters for the immunocompromised.
There is also disagreement among some medical professionals on not only the necessity of boosters for the general public at this time, but the ethics of providing third doses to some while billions around the world remain unvaccinated.
The FDA has not granted full approval to Pfizer’s COVID-19 vaccine; it remains under Emergency Use Authorization, which means it is completely voluntary and its recipients are entitled to provisions calling for fully informed consent.